ocal treatment of craniomandibular myofascial pain with the 5-HT3 receptor antagonist granisetron. A randomized and double-blind study. - Granisetron for myofascial pain

Karolinska Institutet0 个研究点目标入组 40 人开始时间: 2006年2月7日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Inclusion criteria are:
•1) age > 18 years
•2) a diagnosis of myofascial pain according to the research diagnostic criteria (RDC; Dworkin and LeResche, 1992)
•3) craniofacial pain = 3 months with an average pain intensity of = 30 mm on a visual analogue scale (VAS) during one week prior to examination
•4) pain upon digital palpation of the masseter and/or the temporalis muscle
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Exclusion criteria are:
•1) systemic inflammatory connective tissue diseases (e.g. rheumatoid arthritis, ankylosing spondylitis, psoriatric arthritis)
•2) whiplash associated disorder (WAD)
•3) fibromyalgia
•4) neuropathic pain or neurological disorders (e.g. myasthenia gravis, oromandibular dystonia)
•5) pain of dental origin
•6) use of muscle relaxants
•7) pregnancy or lactation
•8) known hypersensitivity to granisetron.

发起方